aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in San Francisco, Allogene Therapeutics is a clinical-stage biotechnology company dedicated to pioneering allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The company's core mission is to revolutionize cancer treatment by developing "off-the-shelf" CAR T products that can be readily available to patients, bypassing the limitations of autologous CAR T therapies. Allogene's vision is to unlock the fourth great wave in cancer treatment, making advanced therapies more accessible and effective.
Notable figures affiliated with Allogene Therapeutics include Dr. Zachary Roberts, who plays a significant role in advancing the company's research and development efforts. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid growth and innovation. Key achievements include the successful development of its allogeneic cell therapy platform and significant progress in clinical trials. Overall, Allogene Therapeutics is making a substantial impact on the future of cancer treatment by offering groundbreaking solutions that promise to improve patient outcomes.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Allogene Therapeutics founded?
Allogene Therapeutics was founded in 2017.
Where is Allogene Therapeutics’s headquarters located?
Allogene Therapeutics’s headquarters is located in South San Francisco, CA, US.
When was Allogene Therapeutics’s last funding round?
Allogene Therapeutics’s most recent funding round was for $250M (USD) in November 2019.
How many employees does Allogene Therapeutics have?
Allogene Therapeutics has 361 employees as of Feb 6, 2024.
How much has Allogene Therapeutics raised to-date?
As of July 05, 2023, Allogene Therapeutics has raised a total of $901.8M (USD) since Nov 1, 2019.
Add Comparison
Total Raised to Date
$901.8M
USD
Last Update Nov 1, 2019
Last Deal Details
$250M
USD
Nov 1, 2019
Post Ipo Equity
Total Employees Over Time
361
As of Feb 2024
Allogene Therapeutics Address
210 E Grand Av
South San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts